AbbVie Inc. (ABBV)
NYSE • Healthcare
August 18, 2026 at 20:00 UTC
About AbbVie Inc.
AbbVie Inc. (NYSE: ABBV) is a healthcare company that discovers, develops, manufactures, and commercializes advanced medicines across immunology, oncology, neuroscience, eye care, and other therapeutic areas around the world. In Drug Manufacturers - General, AbbVie generated $61.2 billion of revenue in FY2025.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
AbbVie Inc.'s Technical Indicators Summary
ABBV’s technical picture is leaning positive, with the price comfortably above short- and long-term moving averages and the classic pivot beneath the market, while ADX near 19 indicates a mild rather than vigorous trend. Momentum readings are constructive—RSI in the low 60s and a strong short-term momentum measure—while MACD shows a modest positive differential. OBV confirms steady volume support and ATR denotes moderate volatility. These elements support a buy orientation without pronounced trend strength. Technical takeaway: Buy — price above multiple averages and confirming volume underpin the bias.
| Indicator | Value |
|---|---|
RSI (14) | 61.67 |
Stochastic %K (14, 3, 3) | 53.67 |
CCI (20) | 58.52 |
WPR (14) | -5.19 |
Momentum (10) | 15.12 |
MFI | 37.47 |
MACD Level (12, 26) | 1.38 |
Bollinger Bands | $239.77 - $264.50 |
ATR (14) | $6.02 (2.33%) |
ADX (14) | 19.43 |
OBV | 23,167,841 |
Classic Pivot Point | $250.04 |
Fibonacci Pivot Point | $250.04 |
Exponential Moving Averages | $230.43 - $251.28(5 indicators) |
Simple Moving Averages | $225.89 - $252.14(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Closing levels show ABBV still elevated versus yesterday, after a 3.43% gap. By the end of trading, the sector had posted a modest gain of 1.59%, offering a gentle tailwind. ABBV taps the debt market with Apogee-linked senior notes, signaling broader capital restructuring.
Trading Volume
Above 10d avg 4.5M
4.6M
vs S&P 500 Today
Strong Outperformance
+4.03%
52-Week Position
Upper range
88.9%
Updated: August 18, 2026 at 20:56 UTC
Quote Summary
ABBV Headlines
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Three high-yield dividend stocks for 2026
April 19, 2026
Valuation Shifts In Major Healthcare Stocks
March 25, 2026
REGENXBIO maps 2026 gene therapy milestones
March 6, 2026